Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Talima Therapeutics

Request full access

Drug delivery company developing customized systems that optimize the local therapeutic performance

San Carlos, United StatesFounded 2004Biotech & Life Sciences

About Talima Therapeutics

Talima Therapeutics was a biopharmaceutical firm established in 2004 and officially founded in 2005, focusing on site-specific drug delivery systems. The company, which is now closed, aimed to develop products that localized therapeutic effects and minimized systemic side effects, thereby addressing unmet needs in the market. Initially led by founding CEO David Henkel-Wallace, Talima's core technology was a proprietary micro-implant system (TMI) designed for the localized application of small-molecule drugs. The company's initial strategic focus was on the dermatology market, where systemic drugs often have adverse effects that limit their use. Conditions like onychomycosis (nail fungus), psoriasis, and severe acne were identified as key target areas where a localized treatment could offer a significant advantage over existing oral medications. The primary product in Talima's pipeline was a micro-implant for treating onychomycosis. This product, which entered Phase I/II clinical trials, was designed to deliver a small-molecule drug directly to the site of the fungal nail infection. This approach intended to provide a safer alternative to widely used oral drugs like terbinafine, which carried risks of systemic side effects. In January 2008, Martin Babler, a former executive at Genentech and Eli Lilly with a background in pharmaceutical science, was appointed President and CEO to guide the company from the proof-of-concept stage toward commercialization. From a financial perspective, Talima Therapeutics secured a significant Series B funding round of $19 million in May 2007. This oversubscribed round was led by US Venture Partners and Latterell Venture Partners, with participation from existing investors De Novo Ventures and Palo Alto Healthcare. The capital was intended to advance the company's product through Phase II clinical trials.

Source: Dealroom company data

At a glance

Status
Closed
Founded
2004
Headquarters
San Carlos, United States
Employees
3
Open positions
None listed
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Testing, Biotechnology, medical implants, Dermatology, Hard Tech, medical testing, DT and LS, science-based
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC May 2007 $19M $76M U.S. Venture Partners · Latterell Venture Partners —
SERIES A✓Equity / VC May 2005 $1.6M $6.4M Palo Alto Investors · DeNovo Ventures —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Talima Therapeutics website traffic

Latest recorded traffic for Talima Therapeutics is 0 monthly website visits, down 100% over the last three months. Talima Therapeutics's team grew 50% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth+50%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Talima Therapeutics in the San Carlos ecosystem

Live from Dealroom

The Talima Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Carlos HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Talima Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Talima Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.